Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)
TD Cowen Maintains Nuvalent(NUVL.US) With Buy Rating
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $110
Nuvalent: Strategic Progress and Pipeline Advancements Solidify Buy Rating
Nuvalent Initiated With a Neutral at UBS
Nuvalent Is Maintained at Overweight by JP Morgan
Nuvalent Analyst Ratings
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $125
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $100 to $135
Nuvalent Price Target Raised to $132.00/Share From $102.00 by BMO Capital
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $100 to $135
Nuvalent Is Maintained at Buy by Stifel
Nuvalent Analyst Ratings
Nuvalent (NUVL) Gets a Buy From Barclays
Goldman Sachs Remains a Sell on Nuvalent (NUVL)
Baird Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $105
Jefferies Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100
Nuvalent Analyst Ratings
Buy Rating Affirmed for Nuvalent: Optimistic Drug Efficacy and Financial Projections
No Data
No Data